Business Wire

VA-HILTON

Share
With Pent Up Demand Expected in 2021, Hilton Introduces Hilton EventReady Hybrid Solutions for Meetings and Events

As we emerge from a year of uncertainties, one business reality seems crystal clear: Hybrid meetings and events will be critical in the near-term. To address this dramatic shift in how people meet and celebrate, Hilton is introducing a set of Hilton EventReady Hybrid Solutions. The new suite of offerings, which will continue to evolve, directs event planners to Hilton’s hybrid-ready hotels while also providing them with planning resources – including an expanded Hilton EventReady Playbook and flexible customer offers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210110005058/en/

With each meeting and event experience delivered by dedicated team members, as part of the Hilton EventReady Hybrid Solutions, participating hotels will have access to comprehensive team member training resources to build and strengthen their knowledge in hybrid events.

“Hilton has remained a leader in the meetings and events industry for more than 100 years by listening intently and innovating quickly to changing customer needs,” said Martin Rinck, executive vice president and chief brand officer, Hilton. “Hilton EventReady Hybrid Solutions were born out of our continued commitment to excellence – from accessing the capabilities of our global portfolio to rolling out a suite of extensive event planner resources and introducing team member training to ensure we can deliver the optimum overall event experience.”

The Hilton EventReady Hybrid Solutions will begin rolling out globally this month. Additionally, the expanded Hybrid Events chapter of the Hilton EventReady Playbook which will include detailed case studies , pro-tips, a glossary of hybrid event terms and more – will also be available in English this month and accessible to customers working with any hotel within the Hilton global portfolio.

The portfolio of hybrid-ready hotels will spotlight the baseline requirements that customers should expect when hosting a small hybrid event, which include:

  • IT Readiness: Each hotel will have undergone an evaluation to assess the available IT bandwidth and infrastructure of the hotel to meet the requirements of small hybrid events. To be deemed “hybrid-ready”, hotels are required to have a minimum amount of incremental and available bandwidth that is above and beyond the hotel’s average circuit utilization level. This requirement allows for seamless communication and connectivity to optimize the hybrid experience within the hotel while providing easy access for virtual attendees.
  • Multi-Site Offering and Express Agreements: These incentives enable customers to book the in-person portion of their event at multiple hybrid-ready Hilton locations as well as create a more seamless contract experience.
  • Expanded Playbook: While the EventReady Playbook is available to customers globally, those looking for in-depth information on planning and executing small hybrid events can access the expanded Hybrid Events chapter, which will continue to evolve alongside customer needs.

As part of the Hilton EventReady Hybrid Solutions, Encore (formerly PSAV) is offering several event technology packages created for small hybrid events at participating hotels in addition to Presentation Stages , a production-ready event solution equipped with critical broadcast technology and staging equipment that helps elevate event messaging and engagement. Presentation Stages offer a clean and safe pre-built location to produce, record and/or broadcast a high-quality online event far exceeding production values available from the typical home or office. The Hilton properties equipped with event technology will accommodate between two to six onsite presenters and up to 50 in-person attendees.

Presentation Stages are currently available to book at Conrad Fort Lauderdale Beach , Hilton Atlanta , Hilton Anatole , Hilton Denver , The Beverly Hilton with several more being made available in Cleveland, Minneapolis, New York, Washington, D.C. and across Europe, Middle East and Africa by the end of the year.

For more information on Hilton EventReady Hybrid Solutions, including a list of the hybrid-ready hotels, visit meetings.hilton.com/eventready .

About Hilton

Hilton (NYSE: HLT) is a leading global hospitality company with a portfolio of 18 world-class brands comprising more than 6,300 properties with nearly one million rooms, in 118 countries and territories. Dedicated to fulfilling its mission to be the world’s most hospitable company, Hilton has welcomed more than 3 billion guests in its more than 100-year history, earned a top spot on the 2020 World’s Best Workplaces list, and was named the 2019 Global Industry Leader on the Dow Jones Sustainability Indices. In 2020, Hilton CleanStay was introduced, bringing an industry-defining standard of cleanliness and disinfection to hotels worldwide. Through the award-winning guest loyalty program Hilton Honors, the more than 110 million members who book directly with Hilton can earn Points for hotel stays and experiences money can’t buy, plus enjoy instant benefits, including contactless check-in with room selection, Digital Key, and Connected Room. Visit newsroom.hilton.com for more information, and connect with Hilton on Facebook , Twitter , LinkedIn , Instagram and YouTube .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 13:30:00 CET | Press release

Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been granted Breakthrough Therapy Designation by the FDA for the adjunctive treatment of major depressive disorder This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated Sep

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma5.1.2026 13:30:00 CET | Press release

- Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP met its primary endpoint of progression-free survival (PFS) - Based on these results, Incyte plans to file a supplemental Biologics License Application (sBLA) for tafasitamab and lenalidomide in addition to R-CHOP in first-line diffuse large B-cell lymphoma (DLBCL) in the first half of 2026 Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years o

SBC Medical Accelerates Global Expansion with Strategic Investment and Alliance witha Leading U.S. MedSpa Platform OrangeTwist as Part of Broader Growth Strategy5.1.2026 13:00:00 CET | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the completion of a strategic minority equity investment and the establishment of a structured collaboration framework with OrangeTwist, a leading U.S.-based MedSpa chain, alongside its longstanding institutional shareholders, Hildred Capital and Athyrium Capital. This transaction marks SBC Medical’s formal entry into the United States—a key global market for medical aesthetics—and represents a major milestone in the Company’s broader global expansion strategy. For more details, click here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210926005/en/ OrangeTwist Supporting 258 affiliated clinics worldwide and managing more than six million patient visits annually, SBC Medical has built one of the largest and

Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)5.1.2026 13:00:00 CET | Press release

Rusfertide Is a First-in-Class Investigational Hepcidin Mimetic That Targets Red Blood Cell Overproduction (Erythrocytosis) in Polycythemia Vera NDA Includes 52-Week Data from Phase 3 VERIFY Study, Which Met the Primary and All Four Key Secondary Endpoints, Showing Rusfertide Provided Durable and Sustained Hematocrit Control and Improved Pre-Specified Patient Reported Outcome Measures Data Underscore the Potential to Shift the Treatment Paradigm for PV Patients to Reduce the Burden of Frequent Phlebotomies and Meaningfully Improve Hematocrit Control Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell product

Macnica Appoints Sebastien Dignard as CEO of Atlantic Region to Accelerate Global Component-to-Solutions and Vertical Strategy5.1.2026 12:00:00 CET | Press release

Macnica leader to strengthen cross-regional collaboration across the Americas and Europe Macnica Inc. today announced the promotion of Sebastien Dignard to chief executive officer of the company’s Atlantic region. In this role, Dignard will lead Macnica’s business across North America, Europe and South America, accelerating the company’s component-to-solutions strategy and strengthening cross-regional collaboration to deliver long-term value for customers and partners across key verticals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260105529342/en/ Sebastien Dignard, CEO, Macnica Atlantic Region Dignard previously served as president of Macnica Americas for two years where he led the organization through a period of growth and transformation across semiconductors, imaging, networking and advanced technologies. Under his leadership, the company shifted from a focus on individual components to value-driven solutions, ecosy

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye